Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 3.38 |
|---|---|
| High | 3.38 |
| Low | 3.38 |
| Bid | 3.62 |
| Offer | 3.82 |
| Previous close | 3.32 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 12.17m |
| Free float | 3.12m |
| P/E (TTM) | -- |
| Market cap | 52.90m USD |
| EPS (TTM) | -3.07 USD |
Data delayed at least 15 minutes, as of Feb 06 2026 07:11 GMT.
More ▼
Announcements
- Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points
- Nutriband CEO Publishes Letter to Shareholders
- Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio
- Nutriband Inc. Signs Letter of Intent with Qvanta Group of Companies to Explore Advanced Technology Solutions for Abuse-Deterrent Pharmaceutical Innovation Strategic Exploration
- Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction
- REPEAT — Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
- Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
- Nutriband Co-Founder Gareth Sheridan Returns as CEO
- Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
- Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology
More ▼
